Thera-SAbDab

ANSUVIMAB

>   Structural Summary
TherapeuticAnsuvimab
TargetZaire Ebolavirus GP1
Heavy ChainEVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSS
Light ChainDIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv Structure5fha [Fvs: HL], 5fhc [Fvs: HL]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Ansuvimab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 101 102 103 104 105 106 107 108 109 110 111 112 113
ansuvimab E V Q L V E S G G G L I Q P G G S L R L S C A A S G F A L R M Y D M H W V R Q T I D K R L E W V S A V G P S G D T T Y A D S V K G R F A V S R E N A K N S L S L Q M N S L T A G D T A I Y Y C V R S D R G V A G L F D S W G Q G I L V T V S S
5fhc E V Q L V E S G G G L I Q P G G S L R L S C A A S G F A L R M Y D M H W V R Q T I D K R L E W V S A V G P S G D T Y Y A D S V K G R F A V S R E N A K N S L S L Q M N S L T A G D T A I Y Y C V R S D R G V A G L F D S W G Q G I L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
ansuvimab D I Q M T Q S P S S L S A S V G D R I T I T C R A S Q A F D N Y V A W Y Q Q R P G K V P K L L I S A A S A L H A G V P S R F S G S G S G T H F T L T I S S L Q P E D V A T Y Y C Q N Y N S A P L T F G G G T K V E I K
5fhc D I Q M T Q S P S S L S A S V G D R I T I T C R A S Q A F D N Y V A W Y Q Q R P G K V P K L L I S A A S A L H A G V P S R F S G S G S G T H F T L T I S S L Q P E D V A T Y Y C Q N Y N S A P L T F G G G T K V E I K
Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 101 102 103 104 105 106 107 108 109 110 111 112 113
ansuvimab E V Q L V E S G G G L I Q P G G S L R L S C A A S G F A L R M Y D M H W V R Q T I D K R L E W V S A V G P S G D T T Y A D S V K G R F A V S R E N A K N S L S L Q M N S L T A G D T A I Y Y C V R S D R G V A G L F D S W G Q G I L V T V S S
5fha E V Q L V E S G G G L I Q P G G S L R L S C A A S G F A L R M Y D M H W V R Q T I D K R L E W V S A V G P S G D T Y Y A D S V K G R F A V S R E N A K N S L S L Q M N S L T A G D T A I Y Y C V R S D R G V A G L F D S W G Q G I L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
ansuvimab D I Q M T Q S P S S L S A S V G D R I T I T C R A S Q A F D N Y V A W Y Q Q R P G K V P K L L I S A A S A L H A G V P S R F S G S G S G T H F T L T I S S L Q P E D V A T Y Y C Q N Y N S A P L T F G G G T K V E I K
5fha D I Q M T Q S P S S L S A S V G D R I T I T C R A S Q A F D N Y V A W Y Q Q R P G K V P K L L I S A A S A L H A G V P S R F S G S G S G T H F T L T I S S L Q P E D V A T Y Y C Q N Y N S A P L T F G G G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)Active
Recorded Developmental Technologyna
INN Year Proposed2020
INN Year RecommendedNone
Companies InvolvedRidgeback Biotherapeutics
Conditions ApprovedZaire ebolavirus infection
Conditions Activena
Conditions Discontinuedna
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy